Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Enzymotec |
---|---|
Information provided by: | Enzymotec |
ClinicalTrials.gov Identifier: | NCT00736034 |
The primary objective of this trial is to assess the ability of Phosphatidylserine-Omega3 to improve cognitive performance in elderly subjects with memory impairment.
This study is a single-center, open-label 15 weeks duration trial to assess efficacy of Phosphatidylserine-Omega3 in elderly subjects with memory impairment.
Condition | Intervention | Phase |
---|---|---|
Memory Impairment |
Dietary Supplement: Phosphatidylserine-Omega3 (SharpPS™-Gold) |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | A Single-Center, Open-Label Study to Assess the Efficacy of SharpPS™-Gold in Elderly Subjects With Memory Impairment |
Estimated Enrollment: | 30 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 65 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
INCLUSION CRITERIA
EXCLUSION CRITERIA
Contact: Rachel Konopinski-Link | +972-3-6973698 | rachell@tasmc.health.gov.il |
Israel | |
The Tel Aviv Sourasky Medical Center, Neurology department | Recruiting |
Tel Aviv, Israel, 64239 |
Principal Investigator: | Veronica Vakhapova, MD | Sourasky Medical Center |
Responsible Party: | Enzymotec ( Inbal Eyal M.Sc ) |
Study ID Numbers: | SharpPS™-Gold 001 |
Study First Received: | August 14, 2008 |
Last Updated: | September 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00736034 |
Health Authority: | Israel: Ministry of Health |
Age Associated Memory Impairment |
Signs and Symptoms Neurologic Manifestations Neurobehavioral Manifestations Memory Disorders |
Nervous System Diseases |